Suppression of nonsense mutations as a therapeutic approach to treat genetic diseases.
about
Rescue of wild-type E-cadherin expression from nonsense-mutated cancer cells by a suppressor-tRNANonsense-mediated mRNA decay: inter-individual variability and human diseaseBlasticidin S inhibits translation by trapping deformed tRNA on the ribosomeAttenuation of nonsense-mediated mRNA decay enhances in vivo nonsense suppressionTranslational read-through as an alternative approach for ocular gene therapy of retinal dystrophies caused by in-frame nonsense mutations.A novel phosphorylation-independent interaction between SMG6 and UPF1 is essential for human NMD.5-azacytidine inhibits nonsense-mediated decay in a MYC-dependent fashion.Increased selectivity toward cytoplasmic versus mitochondrial ribosome confers improved efficiency of synthetic aminoglycosides in fixing damaged genes: a strategy for treatment of genetic diseases caused by nonsense mutationsNonsense-mediated decay in genetic disease: friend or foe?A new series of small molecular weight compounds induce read through of all three types of nonsense mutations in the ATM gene.The designer aminoglycoside NB84 significantly reduces glycosaminoglycan accumulation associated with MPS I-H in the Idua-W392X mouse.Expanding rare disease drug trials based on shared molecular etiologyModulation of efficiency of translation termination in Saccharomyces cerevisiae.Biogenesis of the Saccharomyces cerevisiae pheromone a-factor, from yeast mating to human disease.Suppression of premature termination codons as a therapeutic approach.The promise of recombinant BMP ligands and other approaches targeting BMPR-II in the treatment of pulmonary arterial hypertensionDevelopment of generic immunoassay for the detection of a series of aminoglycosides with 6'-OH group for the treatment of genetic diseases in biological samples.Regulation of nonsense-mediated mRNA decay: implications for physiology and disease.NMD: a multifaceted response to premature translational termination.A generalizable pre-clinical research approach for orphan disease therapyReadthrough strategies for therapeutic suppression of nonsense mutations in inherited metabolic disease.Role of SMG-1-mediated Upf1 phosphorylation in mammalian nonsense-mediated mRNA decay.Antisense oligonucleotide-directed inhibition of nonsense-mediated mRNA decayHydroxylation and translational adaptation to stress: some answers lie beyond the STOP codon.Assessing the activity of nonsense-mediated mRNA decay in lung cancer.Suppressing nonsense--a surprising function for 5-azacytidine.When Proteins Start to Make Sense: Fine-tuning Aminoglycosides for PTC Suppression Therapy.Aminoglycoside-mediated promotion of translation readthrough occurs through a non-stochastic mechanism that competes with translation termination.Antisense suppression of the nonsense mediated decay factor Upf3b as a potential treatment for diseases caused by nonsense mutations.Targeting nonsense-mediated mRNA decay in colorectal cancers with microsatellite instability
P2860
Q24320146-911C7E7A-D054-4333-914F-08B622EA867DQ27015298-1C17F3A3-D880-41F5-A465-625B337D1ECCQ27678912-1E1A6412-66A6-47AD-8A80-23530A1B9FCFQ28486134-D9B8FFF8-7C0A-48CA-8135-83BE3925FB57Q34041207-673CED1D-3149-4B6F-8BF6-A188DB2F5B7FQ34044484-50C1C9FB-AFE9-4104-A7DE-48669823A1C8Q34443734-B94F12E7-2317-42A4-B84F-8AAFBF56D5C2Q34475657-A99E5A1E-7FD7-48B4-8CAB-2DE3EEFEE6ABQ34658988-AE0C6935-250C-4E1C-B28B-0702B77D46B5Q34775214-38527032-6CA6-4150-B5BA-A0E3E51D9059Q35661233-6D3D2D4A-DA53-4B9F-9DD2-C83BD3CD5D77Q35993017-984062BB-CA57-41F9-9099-31FF5EDA7525Q36147322-309A7C17-D097-4FFB-9B44-0DF35C6A7B27Q36194945-091CAD17-92A1-4296-9BC0-506831C7D851Q36203719-D59EE81D-9F17-4067-9AF3-A6570A9FB37EQ36457064-023C8BA6-1DBF-42C5-825A-7F24D825B01CQ36533566-C23F83A7-AB9E-42A0-94EB-82ACF3B78273Q36864323-3E5C7106-2A80-4826-A5C7-EFE348EBF771Q37675497-EA6F1CED-9E78-4A76-A563-7FC483302C66Q38019219-C5C2D2F9-38EB-4414-B29E-AC585157F715Q38072030-466F4172-1BD2-4C19-A66B-5CD831175D08Q38077285-7EA7637B-3268-43E0-8B46-B4C2CCBAEA5BQ38272778-75B20F70-A614-409A-A541-FBB64668EE0EQ38732490-B9A5E4AF-B9FB-4045-A13F-E6914748F500Q41625526-F9A4B160-03E2-41D9-9FD6-4FEB28017D74Q41895916-17C261F1-94E8-45AA-A26A-26E4125933FAQ42142778-C6D4CD06-0B8F-47E2-93D1-E3D7F110F973Q47206251-BF1296CB-0C77-4A15-819A-478B9A99150CQ48241302-E6F1C906-1799-421E-939A-7EA6284F1799Q58381234-8D00FD47-58DA-49BB-8B49-1905840B72BF
P2860
Suppression of nonsense mutations as a therapeutic approach to treat genetic diseases.
description
2011 nî lūn-bûn
@nan
2011 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
name
Suppression of nonsense mutations as a therapeutic approach to treat genetic diseases.
@ast
Suppression of nonsense mutations as a therapeutic approach to treat genetic diseases.
@en
type
label
Suppression of nonsense mutations as a therapeutic approach to treat genetic diseases.
@ast
Suppression of nonsense mutations as a therapeutic approach to treat genetic diseases.
@en
prefLabel
Suppression of nonsense mutations as a therapeutic approach to treat genetic diseases.
@ast
Suppression of nonsense mutations as a therapeutic approach to treat genetic diseases.
@en
P2860
P356
P1476
Suppression of nonsense mutations as a therapeutic approach to treat genetic diseases.
@en
P2093
David M Bedwell
Kim M Keeling
P2860
P304
P356
10.1002/WRNA.95
P577
2011-07-06T00:00:00Z